Massive Bio makes first strategic AI investment in Rivvi

Massive Bio announced its inaugural strategic investment in Rivvi AI at Ai4 2026 in Las Vegas, pairing oncology matching intelligence with agentic healthcare workflows. The companies aim to move more patients from identification to action across clinical trials, care-gap closure, adherence, and other complex-care programs.

Why it matters: - Massive Bio is extending beyond oncology intelligence into the workflow layer that turns patient matches into completed action. - The deal aims to connect clinical validation, personalized outreach, and human navigation in one AI-enabled system. - The companies are targeting clinical trials, medication adherence, care-gap closure, and other complex-care workflows where speed and follow-through affect patient access.

What happened: - Massive Bio announced at Ai4 2026 in Las Vegas that it made a strategic investment in Rivvi AI. - The transaction is Massive Bio’s first strategic investment in another AI company. - Financial terms were not disclosed. - The investment builds on existing collaboration between Massive Bio and Rivvi across oncology trial programs. - Massive Bio and Rivvi plan to align product and go-to-market efforts across healthcare and life sciences.

The details: - Massive Bio’s strategy now includes building core AI products and selectively investing in complementary technologies that expand its platform. - Massive Bio’s oncology intelligence layer structures clinical and biomarker data, identifies relevant trials, and supports navigation. - Rivvi provides an agentic AI layer that turns each match into a governed, auditable workflow. - Rivvi’s system can reach patients, surface barriers, coordinate next steps, and escalate to human teams. - Massive Bio said its neuro-symbolic, multi-agent matching system was prospectively evaluated in 3,804 patients during routine oncology operations. - The peer-reviewed study reported more than 17,000 oncologist-confirmed matches, an F1 score of 0.82, and trial matching four times faster than conventional workflows. - Rivvi has powered more than two million patient interactions across more than 500,000 patients. - Rivvi serves health systems, payers, pharmacies, PBMs, and life sciences organizations. - Rivvi’s platform is HIPAA compliant and SOC 2 Type II, with business associate agreements available. - Rivvi can be deployed without a new electronic medical record integration. - Massive Bio’s Reticulum Nexus suite includes SYNERGY-AI and NexusPulse for explainable patient-trial matches, prioritized cohorts, and next-best-action signals. - Rivvi’s orchestrator agent learns an organization’s programs, policies, and systems, then runs outreach, barrier discovery, scheduling, consent capture, workflow triggers, and escalation paths. - Clinicians, navigators, sites, and support teams receive structured context to complete the next step, from referral or prescreening to appointment, care intervention, or patient support. - Massive Bio operates across 17 countries. - Massive Bio is a recipient of the DiMe Seal and is listed in the CMS Medicare App Library. - Massive Bio is a founding member of CancerX and participates in the White House Cancer Moonshot initiative.

Between the lines: - The investment reflects a push to close a long-standing gap between finding eligible patients and getting them into action. - In oncology, that gap is especially costly because trial windows can close quickly and eligibility rules keep getting more complex. - The companies are positioning AI as capacity-building infrastructure, not as a replacement for clinical judgment. - The architecture emphasizes governance, auditability, and human escalation to make enterprise AI easier to trust in regulated healthcare settings. - Massive Bio is also signaling that it wants to act as both a platform company and an ecosystem investor.

What's next: - Massive Bio and Rivvi plan to deepen integration across trial matching, patient outreach, navigation, and support workflows. - The companies intend to use the combined stack across pharmaceutical, health system, payer, pharmacy, nonprofit, and community outreach programs. - Massive Bio said the transaction creates a repeatable model for evaluating and investing in AI companies that strengthen the patient journey. - Rivvi said the partnership should help life sciences and complex-care programs reach more patients with better timing and human support.

The bottom line: - Massive Bio is betting that validated oncology intelligence plus governed conversational AI can move more patients from match to action at scale.